Company Overview

The Oncology Institute, Inc. (TOI) is a value-based oncology care provider focused on delivering comprehensive cancer treatment services primarily in the United States. The company operates within the healthcare services and oncology industries, emphasizing community-based cancer care with an integrated clinical and financial model. TOI’s core offering centers on medical oncology, including infusion services, radiation oncology (through partnerships), and clinical research, with a strategic emphasis on risk-based and value-oriented reimbursement arrangements.

The company generates revenue primarily through patient care services reimbursed by commercial insurers, Medicare, and managed care organizations, including downside-risk and shared-savings contracts. TOI serves a patient population largely composed of Medicare Advantage and managed Medicaid members. Its positioning is differentiated by its focus on transitioning oncology care from traditional fee-for-service models to value-based care structures. TOI was founded in the mid-2000s and expanded organically before becoming publicly listed in 2021 through a business combination, which accelerated its growth strategy and access to capital.

Business Operations

TOI operates through a network of outpatient oncology clinics delivering chemotherapy, immunotherapy, hematology services, and supportive care. Its business model integrates medical oncology services, pharmacy and infusion operations, and clinical trials, enabling care coordination across the treatment lifecycle. A key operational component is The Oncology Institute Clinical Research, which conducts Phase I–IV trials and provides patients access to investigational therapies.

Operations are primarily domestic, with no material international clinical operations disclosed in public filings. The company leverages proprietary care pathways, data analytics, and care management infrastructure to manage cost and outcomes under value-based arrangements. TOI maintains relationships with payers and health plans rather than pharmaceutical manufacturing or device development, and no material joint ventures or international subsidiaries have been consistently disclosed across public sources. Where disclosures vary, data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, TOI is focused on expanding value-based oncology contracts, increasing clinic density in existing markets, and improving margins through scale and operational efficiencies. Growth initiatives have included de novo clinic openings and selective acquisitions of oncology practices to expand patient lives under management. The company has publicly emphasized risk-bearing arrangements as a long-term differentiator, positioning itself as a partner to payers seeking cost containment and quality improvements in oncology care.

TOI has invested in clinical research capabilities and care delivery technology to support pathway adherence and population health management. Notable subsidiaries consistently referenced in public disclosures include The Oncology Institute Clinical Research. While the company has announced acquisition activity historically, details and valuation impacts vary across reporting periods; therefore, transaction-specific impacts are data inconclusive based on available public sources.

Geographic Footprint

TOI’s operations are concentrated in the Western United States, with a significant presence in California, which represents its largest market by clinic count and patient volume. Additional operations extend into Arizona, Nevada, Florida, and select other states, reflecting a regional expansion strategy rather than a nationwide footprint.

The company’s headquarters and executive operations are based in California, and all reported revenue is derived from U.S.-based healthcare services. TOI does not report material international investments or overseas clinical operations, and its geographic influence remains domestic according to publicly available filings and investor disclosures.

Leadership & Governance

TOI was founded by physician leadership with a clinical-first approach to oncology care delivery. Governance and strategic direction emphasize physician-led management, value-based care adoption, and payer collaboration. The leadership team combines clinical expertise with healthcare operations and public company experience.

Key executives include:

• Daniel Virnich, M.D. – Chief Executive Officer
• Ronald Andrews – Chief Financial Officer
• Kimberly Blackwell, M.D. – Chief Medical Officer
• Stephen Purcell – Chief Operating Officer

The leadership philosophy centers on aligning clinical decision-making with cost accountability and patient outcomes. Where executive roles or titles have changed across reporting periods, information has been reconciled using the most consistently reported public disclosures; discrepancies are data inconclusive based on available public sources.